Rinvoq ER 30 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26F97R2
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,136
Award facts
- Contract value 100% obligated
- $12,135.75 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,135.75 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on January 22, 2026, with completion targeted for January 23, 2026. This firm fixed-price, non-set-aside contract is performed at the contractor's location in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen's parent company, Cencora, Inc., which holds a substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at up to $999,999,999 through December 2031, serving as the primary vehicle for pharmaceutical and medical supply delivery to support military healthcare programs globally.
AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The company competes on a full and open basis for federal contracts and has demonstrated extensive capability in delivering a comprehensive range of pharmaceutical products across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical supplies. This delivery order represents a routine procurement of baricitinib (RINVOQ) tablets, a rheumatoid arthritis treatment, under the larger IDC framework that enables efficient fulfillment of essential pharmaceutical commodities required by military treatment facilities and other federal medical institutions.
Quick answers
Who was awarded contract SPE2DR26F97R2?
SPE2DR26F97R2 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 22, 2026.
How much is contract SPE2DR26F97R2 worth?
The government has obligated $12,136 on SPE2DR26F97R2.
Is contract SPE2DR26F97R2 an order under another contract?
Yes. SPE2DR26F97R2 is a delivery order under SPE2DR25D3505, an indefinite delivery contract.
Was contract SPE2DR26F97R2 competed?
The extent of competition for SPE2DR26F97R2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award